Waxman D
J Int Med Res. 1977;5 Suppl 5:99-110.
A double-blind comparative study of clomipramine and diazepam was carried out in patients suffering from phobic and obsessional disorders. Nineteen doctors submitted 58 patients. Seventeen patients withdrew from the trial, twelve because of side-effects. Forty-one patients completed the trial and of these 14 were on clomipramine and 27 were taking diazepam. Patients were assessed for phobias, obsessions, general psychiatric symptoms and side-effects and each was rated on a special symptom inventory at 0, 2, 4 and 6 weeks of treatment. A General Health Questionnaire and Burns Questionnaire was completed for each patient at the beginning and end of the study. General level of anxiety for diffuse phobic anxiety and situational anxiety for illness and death fears responded better to clomipramine than to diazepam. Global assessment showed significantly more progress on clomipramine than diazepam between weeks 4 and 6.
对患有恐惧症和强迫症的患者进行了氯米帕明和地西泮的双盲对照研究。19名医生提交了58名患者。17名患者退出试验，其中12名是因为副作用。41名患者完成了试验，其中14名服用氯米帕明，27名服用地西泮。对患者的恐惧症、强迫症、一般精神症状和副作用进行评估，并在治疗的0、2、4和6周时根据一份特殊症状清单对每位患者进行评分。在研究开始和结束时，为每位患者填写了一份一般健康问卷和伯恩斯问卷。弥漫性恐惧焦虑的总体焦虑水平以及对疾病和死亡恐惧的情境性焦虑对氯米帕明的反应比对地西泮更好。整体评估显示，在第4周和第6周之间，氯米帕明比地西泮有更显著的进展。
